User:Alexander Rudecki/Sandbox 1: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
← Older editNewer edit →
No edit summary
No edit summary
Line 59: Line 59:
==Location==
==Location==


DromeQC is known to localize in the brain and peripheral nerves of ''D. melanogaster''. This fact was unveiled by the discovery of adipokinetic hormone; this protein has an N-terminal pGlu, supporting that DromeQC is involved in its post translational modification. Adipokinetic hormone was found to localize in neurone and nerve endings by immunohistochemistry, suggesting that it functions as a locally released modulator in tissues such as heart and skeletal muscle<ref>PMID: 6342796</ref>. Thus, It has been suggested that DromeQC is part of the secretory pathway, being targeted to secretory vesicles where hormone maturation takes place. This claim is supported by a 27 residue signal sequence contained at the N-terminus of DromeQC. Further support stems from immunohistochemical evidence that DromeQC and its modified substrate are excreted from the cell, where they can be found in the extracellular medium<ref name="schilling"/>.
DromeQC is known to localize in the brain and peripheral nerves of ''D. melanogaster''<ref name="schilling"/>. This fact was unveiled by the discovery of adipokinetic hormone; this protein has an N-terminal pGlu, supporting a post translational modification via DromeQC<ref>PMID: 2117437</ref>. Adipokinetic hormone was found to localize in neurone and nerve endings by immunohistochemistry, suggesting that it functions as a locally released modulator in tissues such as heart and skeletal muscle<ref>PMID: 6342796</ref>. Thus, It has been suggested that DromeQC is part of the secretory pathway, being targeted to secretory vesicles where hormone maturation takes place<ref name="schilling"/>. This claim is supported by a 27 residue signal sequence contained at the N-terminus of DromeQC<ref name="schilling"/>. Further support stems from immunohistochemical evidence that DromeQC and its modified substrate are excreted from the cell, where they can be found in the extracellular medium<ref name="schilling"/>.




Revision as of 19:51, 31 March 2014

IntroductionIntroduction

Drosophila melanogaster glutaminyl cyclase (DromeQC but also known as CG10487 CG32412 or Dmel\CG32412) is a globular protein part of the α/β-hydrolase superfamily. DromeQC is an aminoacyltransferase (EC 2.3.2.5) that acts on N-terminal glutamine or glutamate residues, producing a stable cap resistant to protease degradation. The human orthologue of DromeQC (hQC) has been implicated in stabilizing amyloid Aβ peptides involved in neurodegenerative disorders such as Alzheimers[1]. It has been shown that DromeQC has a similar overall fold to hQC, as well as a conserved active site[2]. Thus DromeQC is an attractive candidate for transgenic models and mechanistic studies.

DNA-->RNA-->ProteinDNA-->RNA-->Protein

DromeQC is encoded by chromosome 3L, locus 64F4-64F5 in the D. melanogaster genome[3]. It is transcribed into a 1622 nucleotide transcript, containing 5' (36 nucleotides) and 3' (83 nucleotides) untranslated regions [3]. The translated protein contains 340 residues corresponding to a M=38,028 Da[4]. It contains a 27 residue signal sequence, suggesting its involvement in the secretory pathway [1].

Protein FamilyProtein Family

DromeQC belongs to the α/β-hydrolase fold superfamily; this superfamily exhibits a β-sheet core (5-8 strands) connected to α helices forming an α/β/α sandwhich[5]. As of present, the ESTHER database (ESTerases and α/β-Hydrolase Enzymes and Relatives) contains 168 protein families[6]. Most of the proteins in this superfamily function via a conserved catalytic triad - a nucleophile, acid and base - with the residues present on the loops of the active site[7]. Further information on catalysis is found in the 'Catalytic Mechanism' section on this page.

It is interesting that DromeQC prevents protein degradation from aminopeptidases, yet theses two enzymes share a common fold and active site residues[8]. This suggests that the enzymes act in a similar manner, with contrasting effects on substrate.

StructureStructure

A 3D ribbon model of DromeQC as determined by X-ray crystallography

Drag the structure with the mouse to rotate

Visual WalkthroughVisual Walkthrough

DromeQC is a consisting of an A Chain and a B Chain. This homodimer can also be viewed in and representations. The backbone of DromeQC can be easily seen as an . Here the polypeptide progression is depicted by the following template:

 Amino Terminus                 Carboxy Terminus 

The of DromeQC consists of either Protein, Ligand, or Solvent in which it was crystallized (water). When DromeQC is colour coated (Alpha Helices,  Beta Strands ) the global fold may be visualized nicely. This fold is driven by residues. The majority of Hydrophobic residues lie in the interior, consistent with the hydrophobic collapse folding theory. Likewise, most Polar residues reside on the exterior where they contact polar solvent molecules. Similarly, , either Anionic (-) or Cationic (+) appear to cluster on the outside of the protein. From these analyses, it can be seen that a salt bridge connects the two monomers.





Figure 1. A 3D graphical representation displaying the homodimer glutaminyl cyclase from Drosophila melanogaster (PDB: 4F9U). Secondary structure is depicted by red (α-helix) and yellow (β-strand) ribbons, glycosyl groups are coloured pinks, while hydrogen bonds between the two monomers are shown by dotted green lines. The active site of QC contains a chelated zinc ion represented by a gray sphere. Also bound to the active site of this crystal structure and depicted as blue is the inhibitor 1-(3,4-dimethoxyphenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea.
Figure 2. Topology of DromeQC[9]

Topology and Overall StructureTopology and Overall Structure

As shown above, DromeQC is made up of 2 identical, independent monomers that come together to form an asymmetric homodimer (Figure 1). The subunits are connected via 4 hydrogen bonds (Chain 1→Chain 2: ARG35 NH2→GLU64 OE2, ARG43 NH2→ASN71 O, ARG43 NH2→PHE75 O, ARG43 NH1→PHE75 O) and surface complementarity. The subunits exhibit a globular α/β-hydrolase fold, characterized by a central twisted β-sheet motif consisting of 5 parallel strands (β1 and β3-β6) and an antiparallel β2 strand (Figure 2). This β-center is flanked by 9 surrounding α-helices; 2 fill the concave face (α5, α7), 7 fill the convex face (α1- α5, α8, α9) with one helix at the edge (α6) of each monomer. DromeQC is glycosylated (with up to 7 carbohydrate moieties) at the N42 position. These polysaccharide tags increased solubility of DromeQC, and appear to have no affect of protein activity. [2].


Within each subunit is 1 cysteine bond (C113→C136) linking the β3 strand to the α3 helix. These cysteine residues are situated close to the active site, and are conserved in the human orthologue suggesting a pivotal role in catalysis[1]. However, when cysteines were replaced with alanines via site-directed mutagenesis, no kinetic differences were observed[2]. In contrast, this mutation did affect structural differences as determined by thermal unfolding experiments[2]. These results correspond to the structural stabilization of this disulfide bond in hQC, and lack of its effect on kinetic activity[10].

Active SiteActive Site

Figure 3. A comparison between the active sites of Drosophila melanogaster DromeQC crystalized either with a PBD150 inhibitor (right, 4F90) or without (left, 4FWU). Protein loops surrounding the active site are denoted in blue, and a key catalytic Zn2+ is shown as a grey sphere, chelated by three residues shown in light blue. The PBD150 inhibitor (red) involve interactions with W296 (yellow), F292 (green), W176 (beige) and D271 (pink).

The active site of DromeQC is located on four loops that lack secondary structure (Figure 3). Using these loops as a scaffold, a catalytic zinc ion is chelated via D131 OD2, E171 OE2, and H297 NE2. Thus, under the absence of substrate or inhibitor, Zn2+ exhibits trivalency (Figure 3). However, when DromeQC was crystalized in presence of a PBD150 inhibitor, Zn2+ was additionally chelated by the PBD150 imidazole moiety[2]. It is plausible that the amide oxygen of glutamine of peptide substrates chelate the zinc ion in a similar fashion, leading to position, polarization, and stabilization for cyclization.

Binding ofomeQCActiveSite.png|thumb|700px|center|Figure 3. A comparison between the active sites of Drosophila melanogaster DromeQC crystalized either with a PBD150 inhibitor (right, 4F90) or without (left, 4FWU). Protein loops surrounding the active site are denoted in blue, and a key catalytic Zn2+ is shown as a grey sphere, chelated by three residues shown in light blue. The PBD150 inhibitor (red) involve interactions with W296 (yellow), F292 (green), W176 (beige) and D271 (pink).]]

FunctionFunction

Figure 4. Cyclization of a terminal glutamine residue via DromeQC.

The N-terminus of many proteins (ie gonadotropin releasing hormone and thyrotropin-releasing hormone) contain a pyroglutamic acid (pGlu) residue[11]. A pGlu ‘cap’ protects these proteins against degradation by aminopeptidases, and influences the conformation of the hormone or its associated receptor, leading to their activation[1]. Cyclization also leads to decreased basicity in the peptide. Though cyclization of Gln-tRNA to pGlu-tRNA has been shown to occur in papaya latex,[12] N terminal pGlu formation must be post translational due to an essential methionine that initiates translation in all organisms.

Catalytic MechanismCatalytic Mechanism

DromeQC is the enzyme responsible for this post-translational processing of polypeptides. DromeQC catalyzes the cyclization of N-terminal glutamine, and to a lesser extent glutamate, into pyroglutamic acid (5-oxo-L-proline, or <Glu) (Figure 4). This enzyme can be categorized as follows:

-transferase (2)
-acyltransferase (2.3)
-aminoacyltransferase (2.3.2)
-acts on glutaminyl/glutamyl residues (2.3.2.5)

The cyclization reaction occurs via a nucleophilic attack of the α-amine on the γ carbon in the glutamine side chain. The enzymatic mechanism for DromeQC is still undetermined, but it seems plausible that it follows that of its human orthologue. In hQC, the N-terminus of the peptide substrate is inserted into the active site pocket, where the γ amide oxygen chelates the catalytic zinc ion[13]. This ion-dipole interaction causes carbonyl polarization, making it a better electrophile. To facilitate the reaction, a conserved glutamate (Glu201) acts as both a general base and acid. Glu201 abstracts a proton from the α-amino group, causing it to nucleophilically attack the γ amide oxygen. This produces a tetrahedral intermediate with a charged oxygen that is stabilized by Zn2+. Glu201 then protonates the γ amide nitrogen, and an amine group is expelled as the carbonyl reforms. Also essential to this mechanism is a conserved aspartate (Asp248) that coordinates/stabilizes the leaving amine group.

LocationLocation

DromeQC is known to localize in the brain and peripheral nerves of D. melanogaster[1]. This fact was unveiled by the discovery of adipokinetic hormone; this protein has an N-terminal pGlu, supporting a post translational modification via DromeQC[14]. Adipokinetic hormone was found to localize in neurone and nerve endings by immunohistochemistry, suggesting that it functions as a locally released modulator in tissues such as heart and skeletal muscle[15]. Thus, It has been suggested that DromeQC is part of the secretory pathway, being targeted to secretory vesicles where hormone maturation takes place[1]. This claim is supported by a 27 residue signal sequence contained at the N-terminus of DromeQC[1]. Further support stems from immunohistochemical evidence that DromeQC and its modified substrate are excreted from the cell, where they can be found in the extracellular medium[1].











ReferencesReferences

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med. 2008 Oct;14(10):1106-11. doi: 10.1038/nm.1872. Epub 2008 Sep 28. PMID:18836460 doi:http://dx.doi.org/10.1038/nm.1872
  2. ↑ 2.0 2.1 2.2 2.3 2.4 Koch B, Kolenko P, Buchholz M, Ruiz Carrillo D, Parthier C, Wermann M, Rahfeld JU, Reuter G, Schilling S, Stubbs MT, Demuth HU. Crystal Structures of Glutaminyl Cyclases from Drosophila melanogaster Reveal Active Site Conservation between Insect and Mammalian QCs. Biochemistry. 2012 Aug 16. PMID:22897232 doi:10.1021/bi300687g
  3. ↑ 3.0 3.1 DromeQC Gene Card. NCBI. [1]
  4. ↑ DromeQC. UniProt. [2]
  5. ↑ Lenfant N, Hotelier T, Velluet E, Bourne Y, Marchot P, Chatonnet A. ESTHER, the database of the alpha/beta-hydrolase fold superfamily of proteins: tools to explore diversity of functions. Nucleic Acids Res. 2013 Jan;41(Database issue):D423-9. doi: 10.1093/nar/gks1154. , Epub 2012 Nov 27. PMID:23193256 doi:http://dx.doi.org/10.1093/nar/gks1154
  6. ↑ Lenfant, N., Hotelier, T., Velluet, E., Bourne, Y., Marchot, P., and A Chatonnet. (2013) ESTHER, the database of the alpha/beta-hydrolase fold superfamily of proteins: tools to explore diversity of functions. Nucleic Acids Research 41: D423-9. [3]
  7. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named family
  8. ↑ Booth RE, Lovell SC, Misquitta SA, Bateman RC Jr. Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site. BMC Biol. 2004 Feb 10;2:2. PMID:15028118 doi:10.1186/1741-7007-2-2
  9. ↑ PDB Sum Entry 4F9U. EMBL-EBI. [4]
  10. ↑ Ruiz-Carrillo, D., Koch, B., Parthier, C., Wermann, M., Dambe, T., Buchholz, M., Ludwig, H., Heiser, U., Rahfeld, J., Stubbs, M. T., Schilling, S., and H. Demuth. (2011) Structures of glycosylated mammalian glutaminyl cyclases reveal conformational variability near the active center. Biochemistry. 50: 6280-6288. DOI: 10.1021/bi200249h
  11. ↑ Goren HJ, Bauce LG, Vale W. Forces and structural limitations of binding of thyrotrophin-releasing factor to the thyrotrophin-releasing receptor: the pyroglutamic acid moiety. Mol Pharmacol. 1977 Jul;13(4):606-14. PMID:196172
  12. ↑ Bernfield MR, Nestor L. The enzymatic conversion of glutaminyl-tRNA to pyrrolidone carboxylate-tRNA. Biochem Biophys Res Commun. 1968 Dec 9;33(5):843-9. PMID:4881333
  13. ↑ Calvaresi M, Garavelli M, Bottoni A. Computational evidence for the catalytic mechanism of glutaminyl cyclase. A DFT investigation. Proteins. 2008 Nov 15;73(3):527-38. doi: 10.1002/prot.22061. PMID:18470930 doi:http://dx.doi.org/10.1002/prot.22061
  14. ↑ Schaffer MH, Noyes BE, Slaughter CA, Thorne GC, Gaskell SJ. The fruitfly Drosophila melanogaster contains a novel charged adipokinetic-hormone-family peptide. Biochem J. 1990 Jul 15;269(2):315-20. PMID:2117437
  15. ↑ Schooneveld H, Tesser GI, Veenstra JA, Romberg-Privee HM. Adipokinetic hormone and AKH-like peptide demonstrated in the corpora cardiaca and nervous system of Locusta migratoria by immunocytochemistry. Cell Tissue Res. 1983;230(1):67-76. PMID:6342796
Retrieved from "https://proteopedia.openfox.io/wiki/index.php?title=User:Alexander_Rudecki/Sandbox_1&oldid=1907791"